Molecure SA presented data on the discovery of the clinical candidate OATD-02, a first-in-class, highly potent dual arginase-1/2 (ARG1/2) inhibitor with excellent activity against intracellular ARG2, thereby holding promise as an immunotherapeutic for cancer.